<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205528</url>
  </required_header>
  <id_info>
    <org_study_id>NN9709-4336</org_study_id>
    <secondary_id>U1111-1189-5627</secondary_id>
    <nct_id>NCT02205528</nct_id>
  </id_info>
  <brief_title>A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The aim of the trial is to
      investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections
      of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2014</start_date>
  <completion_date type="Actual">December 2, 2015</completion_date>
  <primary_completion_date type="Actual">December 2, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Day 1; Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Day 1; Week 8; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in body weight</measure>
    <time_frame>Day 1; Week 8; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Day 1; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-prandial plasma glucose level</measure>
    <time_frame>Day -7; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-prandial insulin level</measure>
    <time_frame>Day -7; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-prandial C-peptide level</measure>
    <time_frame>Day -7; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>Day 1; Week 12</time_frame>
    <description>According to the Homeostasis Model Assessment (HOMA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 1; Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent HbA1c</measure>
    <time_frame>Day 1; Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment Period: Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period: NNC0090-2746 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period: Liraglutide QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.</description>
    <arm_group_label>Treatment Period: Liraglutide QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.</description>
    <arm_group_label>Treatment Period: Placebo QD</arm_group_label>
    <arm_group_label>Treatment Period: NNC0090-2746 QD</arm_group_label>
    <arm_group_label>Treatment Period: Liraglutide QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.</description>
    <arm_group_label>Treatment Period: Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0090-2746</intervention_name>
    <description>NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.</description>
    <arm_group_label>Treatment Period: NNC0090-2746 QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants aged 18 to 70 years, inclusive

          -  Active diagnosis of T2D for greater than or equal to (&gt;/=) 3 months

          -  For females of childbearing potential and males with female partners of childbearing
             potential, agreement to use highly effective contraceptive measures

          -  Treated with a stable dose of metformin for at least 8 weeks prior to randomization,
             and expected to remain at the same stable dose throughout study participation

          -  Hemoglobin A1c (HbA1c) &gt;/= 7.2% and less than or equal to (&lt;/=) 10.5%

          -  Fasting plasma glucose (FPG) less than (&lt;) 250 milligrams per deciliter (mg/dL)

          -  C-peptide greater than (&gt;) 1.5 nanograms per milliliter (ng/mL)

          -  Body mass index (BMI) &gt;/= 27 kilograms per meter-squared (kg/m^2) and &lt;/= 44 kg/m^2

          -  Stable weight (+/- 5%) within 12 weeks prior to Screening

          -  Willing and able to maintain existing diet and exercise habits throughout the study

          -  Capable of performing SC self-injections on a daily basis during the study

        Exclusion Criteria:

          -  Females who are pregnant or lactating

          -  History of type 1 diabetes (T1D), diabetes resulting from pancreatic injury, or
             secondary forms of diabetes such as Cushing's Syndrome or acromegaly

          -  History of acute metabolic complications such as diabetic ketoacidosis or state of
             hyperosmolar hyperglycemia

          -  History of clinically significant diabetic complications such as diabetic
             proliferative retinopathy or severe diabetic neuropathy (requiring treatment with
             antidepressants or opioids)

          -  History of severe hypoglycemia within 6 months prior to Screening

          -  History of chronic gastrointestinal (GI) conditions that could impede gastric emptying
             or potentially affect the interpretation of the study data

          -  History of weight loss surgery or weight loss procedure involving the GI tract, such
             as gastric bypass, gastric stapling, or gastric banding

          -  History of an eating disorder (e.g., bulimia, anorexia)

          -  History of malignancy (except treated basal or squamous cell skin cancer) within 5
             years prior to Screening

          -  Personal or family history of medullary thyroid carcinoma

          -  History of multiple endocrine neoplasia syndrome type 2

          -  History of chronic or acute pancreatitis or hemochromatosis

          -  History of significant cardiovascular disease (such as congestive heart failure New
             York Heart Association Class II to IV, myocardial infarction within the previous 6
             months, coronary disease, or uncontrolled hypertension)

          -  History of clinically significant renal or liver disease

          -  History of hypersensitivity or previous intolerance to incretin or glucagon analogues

          -  Elevations in lipase or amylase levels at Screening &gt; 1.5 times the upper limit of
             normal (ULN) and considered clinically significant by the investigator

          -  Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG), or
             hepatitis C antibody test at Screening

          -  Receipt of an investigational drug within 30 days or 5 half-lives, whichever is
             longer, prior to Screening, or active enrollment in another investigational medication
             or device study

          -  Any condition, disorder, or abnormal laboratory test findings at screening that, in
             the judgment of the investigator, would interfere with the participant's ability to
             comply with all study requirements, or would require the administration of a treatment
             during the study that could potentially affect the interpretation of the study data,
             or would place the participant at unacceptable risk by his/her participation in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <zip>90716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Frias JP, Bastyr EJ 3rd, Vignati L, Tsch√∂p MH, Schmitt C, Owen K, Christensen RH, DiMarchi RD. The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metab. 2017 Aug 1;26(2):343-352.e2. doi: 10.1016/j.cmet.2017.07.011.</citation>
    <PMID>28768173</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

